Industry Update: Interim 503A and 503B Bulks Lists New Revisions FDA puts some peptides off limits The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157, Semaglutide, And Wellness Peptides: What's Actually Allowed In California? Holt Law FDA Compliance for Peptide Therapy and BPC 157 Holt Law Navigating the FDA's Final Interim Policy on Compounding with Bulk Drug Substances: A Guide for 503A Pharmacies and 503B Outsourcing Facilities Buchanan Ingersoll & Rooney PC